Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hepion Pharmaceuticals Inc HEPA

Healthcare
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address... see more

Recent & Breaking News (NDAQ:HEPA)

Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat

GlobeNewswire October 20, 2022

Hepion Pharmaceuticals to Participate in the ThinkEquity Conference

GlobeNewswire October 19, 2022

Hepion Pharmaceuticals to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

GlobeNewswire September 26, 2022

Upcoming Presentation at Joint Meeting of ISBRA and ESBRA to Highlight Potential of Hepion Pharmaceutical's Rencofilstat to Treat Alcohol-Related Liver Disease

GlobeNewswire September 14, 2022

Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2 'ALTITUDE-NASH' Liver Function Trial

GlobeNewswire September 12, 2022

Hepion Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 8, 2022

Hepion Pharmaceuticals Announces Initiation of Phase 2b 'ASCEND-NASH' Trial

GlobeNewswire August 31, 2022

Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders

GlobeNewswire July 22, 2022

Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati

GlobeNewswire June 28, 2022

Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

GlobeNewswire June 24, 2022

Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma

GlobeNewswire June 20, 2022

Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress(TM) 2022

GlobeNewswire June 15, 2022

Hepion Pharmaceuticals Appoints Accomplished Life Sciences Industry Veteran, Dr. Launa J. Aspeslet, as Chief Operating Officer

GlobeNewswire June 14, 2022

Hepion Pharmaceuticals Urges Shareholders to Vote "FOR" All Proposals Ahead of its Upcoming Annual Meeting

GlobeNewswire May 31, 2022

CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc.

GlobeNewswire May 27, 2022

Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress

GlobeNewswire May 27, 2022

Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial

GlobeNewswire May 3, 2022

Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference

GlobeNewswire March 7, 2022

Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company's Strategic Medical Affairs in Asia

GlobeNewswire February 15, 2022

Hepion Pharmaceuticals to Present at BIO CEO & Investor Conference

GlobeNewswire February 14, 2022